Apolipoprotein E gene promoter -219G->T polymorphism increases LDL-cholesterol concentrations and susceptibility to oxidation in response to a diet rich in saturated fat

Am J Clin Nutr. 2004 Nov;80(5):1404-9. doi: 10.1093/ajcn/80.5.1404.

Abstract

Background: The apolipoprotein E (APOE) gene promoter polymorphism (-219G-->T) has been associated with increased risk of myocardial infarction, premature coronary artery disease, and decreased plasma apolipoprotein E concentrations.

Objective: We aimed to determine in healthy subjects whether this polymorphism modifies the susceptibility of LDL to oxidation and the lipid response to the content and quality of dietary fat.

Design: Fifty-five healthy men with the APOE3/E3 genotype (7 GG, 38 GT, and 10 TT) completed 3 dietary periods, each lasting 4 wk. The first was a saturated fatty acid (SFA)-rich diet [38% fat-20% SFA and 12% monounsaturated fatty acid (MUFA)-and 47% carbohydrates (CHO)], which was followed by a CHO-rich diet (30% fat-<10% SFA and 12% MUFA-and 55% CHO) or a MUFA-rich diet (38% fat-<10% SFA and 22% MUFA-and 47% CHO) in a randomized crossover design. At the end of each dietary period, LDL oxidation susceptibility, lipids, and lipoproteins were measured.

Results: Compared with carriers of the G allele, TT subjects had a significantly (P < 0.05) shorter lag time after the SFA diet. The replacement of the SFA diet by the CHO or MUFA diet induced a greater increase (P < 0.05) in lag time in the TT subjects than in the GG or GT subjects. Carriers of the T allele had higher LDL-cholesterol (P < 0.05) and apolipoprotein B (P < 0.05) plasma concentrations after the SFA diet than did GG subjects. Compared with GG subjects, carriers of the T allele had a significantly (P < 0.05) greater decrease in LDL cholesterol and apolipoprotein B when they changed from the SFA to the CHO diet.

Conclusion: The -219G-->T polymorphism may partially explain differences in individual responses to diet.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apolipoprotein E3
  • Apolipoproteins E / drug effects
  • Apolipoproteins E / genetics*
  • Cardiovascular Diseases / etiology
  • Cholesterol, LDL / blood*
  • Cholesterol, LDL / drug effects
  • Dietary Fats / pharmacology*
  • Fatty Acids / administration & dosage
  • Fatty Acids / pharmacology*
  • Genotype
  • Humans
  • Male
  • Oxidation-Reduction / drug effects
  • Polymorphism, Genetic / drug effects*
  • Risk

Substances

  • Apolipoprotein E3
  • Apolipoproteins E
  • Cholesterol, LDL
  • Dietary Fats
  • Fatty Acids